Physician profile
Michael Johnson
NPI 1205104411
$28,421.67
in general payments reported to CMS, 2019-2025
39 companies · $7,205 in 2025
The $7,205 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $517 · 2022: $1,016 · 2023: $2,313 · 2024: $17K · 2025: $7,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $20K · Food and Beverage: $6,361 · Travel and Lodging: $986 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $19,525.00 |
| Food and Beverage | $6,360.63 |
| Travel and Lodging | $985.53 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $21,983.98 | 2021-2025 | Xcopri |
| Ucb, INC. | $1,266.30 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Abbvie INC. | $569.07 | 2023-2025 | |
| Neurelis, INC. | $360.06 | 2021-2024 | Valtoco |
| Medtronic, INC. | $359.47 | 2021-2023 | Percept PC Brainsense |
| Amgen INC. | $353.27 | 2021-2025 | Uplizna |
| Amneal Pharmaceuticals LLC | $330.08 | 2021-2024 | Rytary, Lyvispah |
| Neurocrine Biosciences, INC. | $327.18 | 2022-2025 | Ingrezza, Ongentys |
| Livanova USA, INC. | $317.12 | 2022-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Pfizer INC. | $277.76 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $237.19 | 2022-2025 | |
| Lundbeck LLC | $169.42 | 2023-2024 | Vyepti, Rexulti |
| Catalyst Pharmaceuticals, INC. | $160.38 | 2024-2025 | |
| Lilly USA, LLC | $155.39 | 2021-2025 | Amyvid, Kisunla |
| Eisai INC. | $130.16 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $122.61 | 2022-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $119.77 | 2023-2024 | Ultomiris |
| Emd Serono, INC. | $111.91 | 2022-2024 | Mavenclad |
| Tanabe Pharma America, INC. | $111.38 | 2022-2024 | |
| Argenx US, INC. | $107.35 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Sumitomo Pharma America, INC. | $100.68 | 2023 | Aptiom |
| Biohaven Pharmaceutical Holding Company LTD. | $98.89 | 2022 | |
| Acorda Therapeutics, INC | $81.50 | 2023-2024 | Inbrija |
| Kyowa Kirin, INC. | $71.85 | 2023-2024 | Nourianz |
| Celgene Corporation | $70.77 | 2023-2025 | Zeposia |
| Immedica Pharma US, INC. | $57.27 | 2023-2024 | |
| Impel Pharmaceuticals INC. | $42.87 | 2022-2023 | Trudhesa |
| Greenwich Biosciences, INC. | $42.50 | 2021 | |
| Genzyme Corporation | $42.37 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $34.50 | 2025 | Xeomin |
| Cycle Pharmaceuticals INC | $33.26 | 2025 | Tascenso Odt |
| Teva Pharmaceuticals USA, INC. | $31.79 | 2024-2025 | Austedo Xr, Austedo Xr |
| Exeltis, USA INC. | $28.87 | 2023 | Slynd |
| Grifols USA, LLC | $23.43 | 2024 | Gamunex-C |
| E.R. Squibb & Sons, L.L.C. | $21.09 | 2022 | |
| Tg Therapeutics, INC. | $20.93 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $20.10 | 2021 | |
| Ethicon US, LLC | $15.02 | 2024 | Harmonic, Echelon Flex |
| Horizon Therapeutics Plc | $14.13 | 2023 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.